These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64. Plan to be flexible: a commentary on adaptive designs. Shih WJ Biom J; 2006 Aug; 48(4):656-9; discussion 660-2. PubMed ID: 16972718 [TBL] [Abstract][Full Text] [Related]
65. Adapting the sample size planning of a phase III trial based on phase II data. Wang SJ; Hung HM; O'Neill RT Pharm Stat; 2006; 5(2):85-97. PubMed ID: 17080765 [TBL] [Abstract][Full Text] [Related]
66. Determining equivalence and the impact of sample size in anti-infective studies: a point to consider. Bristol DR J Biopharm Stat; 1996 Jul; 6(3):319-26. PubMed ID: 8854235 [TBL] [Abstract][Full Text] [Related]
67. Sample sizes for experiments with multivariate repeated measures. Guo X; Johnson WD J Biopharm Stat; 1996 May; 6(2):155-76. PubMed ID: 8732911 [TBL] [Abstract][Full Text] [Related]
68. An introduction to the statistical design of phase III cancer clinical trials. Sylvester R Eur Urol; 1997; 31 Suppl 1():65-71. PubMed ID: 9076487 [TBL] [Abstract][Full Text] [Related]
69. Phase III design: principles. Buyse M Chin Clin Oncol; 2016 Feb; 5(1):10. PubMed ID: 26932434 [TBL] [Abstract][Full Text] [Related]
70. [Estimation of the sample size in clinical and epidemiological investigations]. Marrugat J; Vila J; Pavesi M; Sanz F Med Clin (Barc); 1998 Sep; 111(7):267-76. PubMed ID: 9789243 [No Abstract] [Full Text] [Related]
71. Evaluation of statistical designs in phase I expansion cohorts: the Dana-Farber/Harvard Cancer Center experience. Dahlberg SE; Shapiro GI; Clark JW; Johnson BE J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 24963024 [TBL] [Abstract][Full Text] [Related]
72. Optimal sample sizes for phase II clinical trials and pilot studies. Stallard N Stat Med; 2012 May; 31(11-12):1031-42. PubMed ID: 22052407 [TBL] [Abstract][Full Text] [Related]
73. Sample size calculations for the design of health studies: a review of key concepts for non-statisticians. Merrifield A; Smith W N S W Public Health Bull; 2012 Sep; 23(7-8):142-7. PubMed ID: 23043746 [TBL] [Abstract][Full Text] [Related]
74. Optimal sample size allocation and go/no-go decision rules for phase II/III programs where several phase III trials are performed. Preussler S; Kieser M; Kirchner M Biom J; 2019 Mar; 61(2):357-378. PubMed ID: 30182372 [TBL] [Abstract][Full Text] [Related]
75. A perspective on clinical significance. Hujoel PP; Armitage GC; García RI J Periodontol; 2000 Sep; 71(9):1515-8. PubMed ID: 11022783 [No Abstract] [Full Text] [Related]
76. An industry statistician's perspective on PHC drug development. Fridlyand J; Yeh RF; Mackey H; Bengtsson T; Delmar P; Spaniolo G; Lieberman G Contemp Clin Trials; 2013 Nov; 36(2):624-35. PubMed ID: 23648396 [TBL] [Abstract][Full Text] [Related]
77. Determination of hazard ratio for progression-free survival considering the tumor assessment schedule in sample size calculation. Tanase T Pharm Stat; 2020 Mar; 19(2):126-136. PubMed ID: 32067336 [TBL] [Abstract][Full Text] [Related]
78. Sample size calculations for trials in health services research. Wood J; Lambert M J Health Serv Res Policy; 1999 Oct; 4(4):226-9. PubMed ID: 10623039 [TBL] [Abstract][Full Text] [Related]